Page 322 - ebook HCC

PROGRAMME
GENEV
EASL HCC SUMMITHCC SUMMIT
321
320 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 321
320
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C83
CARCINOVIC STUDY: CLINICAL COURSE Results: To date, 30 HIV/HCV pts (n=27 men (90%), median age = 49 years [43-65])
AND RADIOLOGICAL FEATURES OF had radiological confirmation of HCC (Prethevic (n=20), HepaVih (n=10)). At diagnosis,
median CD4 count was 345/mm [24-1121] and aFP was 31.7 ng/ml [3.5-18740]. The
3
HEPATOCELLULAR CARCINOMA IN HIV/HCV clinical course of the liver disease was measured by two variables: the median duration
CO-INFECTED PATIENTS from cirrhosis to HCC diagnosis, 4.5 years [0-18], and the median duration from first
positive HCV serology to HCC diagnosis, 15 years [6-15]. The radiological diagnosis
showed nodular forms in 24/30 pts (80%) with 1 nodule in 17/24 pts (70.8%), and tumoral
portal thrombosis in 6/30 pts (20%). The median diameter of the main nodule was 25
Moana Gelu-Simeon , Maïté Lewin , Rodolphe Sobesky , Marita Ostos , mm [12-125]. Overall free survival was 65% and 35% at 12 and 60 months respectively.
1
2
1
1
Elina Teicher , Faroudy Boufassa , Laurence Meyer , Hélène Fontaine , A combination of curative treatments and a palliative combination in 16/30 pts (53.3%)
3
4
4
5
Dominique Salmon-Céron , Jean-Claude Trinchet , Jean-Charles Duclos-Vallée 1 and in 9/30 cases (30%), respectively. A palliative treatment was performed in 5/30 pts
6
7
2
1 Centre Hépato-Biliaire, Radiology, Paul Brousse hospital, Villejuif, Infectious disease, (16.7%). 16/30 patients (53.3%) died during a median follow-up of 16.5 months [1-74]). In
3
4 Epidemiology INSERM U1018, Bicêtre hospital, Le Kremlin-Bicêtre, 11/30 pts (36.7%) the death was due to tumor progression.
6
5 Hepatology, Infectious disease, Cochin hospital, Paris,
7 Hepatology, Jean Verdier hospital, Bondy, France Conclusion: In our series we observed (1) a classical radiological presentation in most
cases, (2) a short clinical course in HIV/HCV co-infected pts with HCC.
Corresponding author’s e-mail: moana.simeon@gmail.com
Introduction: A significant increase in decompensated cirrhosis and occurrence of
hepatocellular carcinoma (HCC) in HIV/HCV co-infected patients (pts) is well established,
partly due to a longer survival life under effective antiviral therapy and faster evolution
of liver disease. To date, the prognosis of HCC in HIV/HCV co-infected pts is globally
poor and there is a lack of radiological data.
Aims: To study clinical course and radiological features of HCC in HIV/HCV co-infected
pts from three national prospective cohorts.
CLINICAL POSTER ABSTRACTS HCC have been created from three multicenter cohorts, (i) Prethevic cohort (n=98 pts) CLINICAL POSTER ABSTRACTS
Methodology: A new cohort untitled Carcinovic, including HIV/HCV co-infected pts with
including HIV/HCV pts with end stage liver disease, (ii) HepaVih cohort (n=1225 pts)
studying the evolution of HIV/HCV co-infected pts, (iii) CirVir cohort (n=1823 pts) including
pts with viral cirrhosis. Cases of HCC were prospectively and retrospectively included
since February 2012. The diagnosis of HCC was primarily based on imaging interpretation
of two experimented radiologists to determine typical imaging features (according to
Barcelona criteria). The clinical and radiological data have been collected at radiological
diagnosis and survival has been analyzed.